News Releases

June 2, 2022
LAVA Therapeutics to Participate at the Jefferies Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer,
» Full Release
June 1, 2022
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its
» Full Release
May 31, 2022
LAVA Therapeutics Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  ( Nasdaq: LVTX ) (LAVA), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of
» Full Release
May 17, 2022
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 ASCO Annual Meeting LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first
» Full Release
May 12, 2022
LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies
UTRECHT, The Netherlands and PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer,
» Full Release
May 5, 2022
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced
» Full Release
April 27, 2022
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced
» Full Release
March 24, 2022
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022 LAVA-1207 Phase 1/2a trial in mCRPC on track to report initial data in H2 2022 New pipeline program: LAVA-1266, a CD123-directed Gammabody™   for
» Full Release
March 10, 2022
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of
» Full Release
March 7, 2022
LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome Pharmacodynamic markers indicate increasing receptor occupancy with increasing doses of LAVA-051 and activation of Vγ9Vδ2 T cells Preclinical data presented on LAVA’s lead
» Full Release